Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check7 days agoChange DetectedThe page's Revision tag has been updated to v3.6.3, replacing the previous v3.6.2. This indicates a minor maintenance update to the site version tag.SummaryDifference0.0%

- Check14 days agoChange DetectedThe revision line on the page was updated from Revision: v3.6.0 to Revision: v3.6.2. This indicates a newer version of the page content.SummaryDifference0.0%

- Check21 days agoChange DetectedRemoved sponsor/investigator identifiers and a drug description line, along with the attribution note, diminishing attribution and navigational context on the study's details page.SummaryDifference0.2%

- Check28 days agoChange DetectedThe study record text adds investigator-related items and navigation sections (including Andrea Ardizzoni and several help/section labels) and updates the revision to v3.6.0, while removing the previous attribution and the older Intervention / Treatment label.SummaryDifference1%

- Check36 days agoChange DetectedThe page revision was updated to v3.5.5, indicating a minor maintenance update to the study details page.SummaryDifference0.0%

- Check57 days agoChange DetectedA CABOSUN trial reference was added to the Publications section, and the previous erratum citation along with its revision tag (v3.5.3) was removed; this represents a bibliographic update to sources cited on the page.SummaryDifference0.1%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.